Why Use Aprepitant Only as a Cough Suppressant in Lung Cancer When at Higher Doses it Could Also Exert an Antitumor Action?-Reference-Cited by-同舟云学术

Why Use Aprepitant Only as a Cough Suppressant in Lung Cancer When at Higher Doses it Could Also Exert an Antitumor Action?

Published:2022-10 Issue:10 Volume:58 Page:727-728
ISSN:0300-2896
Container-title:Archivos de Bronconeumología
language:en
Short-container-title:Archivos de Bronconeumología

Author:

Muñoz Miguel,Muñoz Miguel E.,Morell Ferran,Coveñas Rafael

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference5 articles.

1. Aprepitant for cough in lung cancer. A randomized placebo-controlled trial and mechanistic insights;Smith;Am J Respir Crit Care Med,2021

2. Aprepitant for cough suppression in advanced lung cancer: a randomized trial;Noronha;Chest,2020

3. The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer?;Muñoz;Cancers (Basel),2020

4. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists;Muñoz;Peptides,2012

5. Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: a case report;Muñoz;Mol Clin Oncol,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antitumor Strategies Targeting Peptidergic Systems;Encyclopedia;2024-03-06

2. Fighting Cancer Using Selective Antagonists Targeting the Substance P/Neurokinin-1 Receptor System;Interdisciplinary Cancer Research;2024

3. Long-term Use of Angiotensin-converting Enzyme Inhibitors Increases Substance P Levels, Which is Involved in the Risk of Lung Cancer;Archivos de Bronconeumología;2023-12

4. Peptidergic Systems as Antitumor Targets: A Right Direction to Fight Cancer?;Cancers;2023-10-13

5. The Neurokinin-1 Receptor: A Promising Antitumor Target;Receptors;2022-11-07